The discovery and characterization of the different CFTR mutations heralded a new era of targeted therapies for CF that includes the promising advent of CFTR modulator therapy that directly augments deficiencies related to CFTR mutations [11,12,13]. This evidence concerns the gene CFTR and cystic fibrosis.